Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CB-307 by Crescendo Biologics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
CB-307 is under clinical development by Crescendo Biologics and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...